Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of LVRNA021 Bivalent Booster
NCT05812014Phase 3Unknown
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of LVRNA021 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by AIM Vaccine Co., Ltd. Primary endpoint: Person-year incidence density of first episodes of virologically-confirmed symptomatic cases of COVID-19. Status: unknown.
02
Drugs
LVRNA021
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05812014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05812014.